Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection

American Journal of Transplantation

Volumn 17, Issue 4, 2017, Pages 931-943

  Boardman, D A ^a   Philippeos, C ^a   Fruhwirth, G O ^b   Ibrahim, M A A ^a,c   Hannen, R F ^d   Cooper, D ^d   Marelli Berg, F M ^d   Watt, F M ^a   Lechler, R I ^a   Maher, J ^a,c   Smyth, L A ^a,e   Lombardi, G ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF EAST LONDON   (United Kingdom)

Author keywords

alloantigen; animal models: murine; basic (laboratory) research science; cellular biology; gene therapy; immune regulation; immunosuppression immune modulation; molecular biology; T cell biology; translational research science

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; HLA ANTIGEN CLASS 1; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOLOGY; HUMAN; HUMAN CELL; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SKIN INJURY; SKIN TRANSPLANTATION; ALLOGRAFT; ANIMAL; BAGG ALBINO MOUSE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; MONONUCLEAR CELL; MOUSE; TRANSPLANTATION TOLERANCE; XENOGRAFT;

ALLOGRAFTS; ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HETEROGRAFTS; HLA-A2 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; RECEPTORS, ANTIGEN; SKIN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 85011340458     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14185     Document Type: Article

References (63)

1. Booth AJ, Grabauskiene S, Wood SC, Lu G, Burrell BE, Bishop DK. IL-6 promotes cardiac graft rejection mediated by CD4 + cells. J Immunol 2011; 187: 5764–5771.
2. Pasquet L, Douet JY, Sparwasser T, Romagnoli P, van Meerwijk JP. Long-term prevention of chronic allograft rejection by regulatory T-cell immunotherapy involves host Foxp3-expressing T cells. Blood 2013; 121: 4303–4310.
3. Sagoo P, Lombardi G, Lechler RI. Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation. Front Immunol 2012; 3: 184.
4. Tsang JY, Tanriver Y, Jiang S, et al. Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression. Transpl Immunol 2009; 21: 203–209.
5. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001; 1: 97–102.
6. Game DS, Lechler RI. Pathways of allorecognition: Implications for transplantation tolerance. Transpl Immunol 2002; 10: 101–108.
7. Safinia N, Leech J, Hernandez-Fuentes M, Lechler R, Lombardi G. Promoting transplantation tolerance; adoptive regulatory T cell therapy. Clin Exp Immunol 2013; 172: 158–168.
8. Meier-Kriesche HU, Kaplan B. The search for CNI-free immunosuppression: No free lunch. Am J Transplant 2011; 11: 1355–1356.
9. Wojciechowski D, Vincenti F. Tofacitinib in kidney transplantation. Expert Opin Investig Drugs 2013; 22: 1193–1199.
10. Burgos D, Gonzalez-Molina M, Ruiz-Esteban P, et al. Rate of long-term graft loss has fallen among kidney transplants from cadaveric donors. Transplant Proc 2012; 44: 2558–2560.
11. Gruessner RW, Gruessner AC. The current state of pancreas transplantation. Nat Rev Endocrinol 2013; 9: 555–562.
12. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: How do they suppress immune responses? Int Immunol 2009; 21: 1105–1111.
13. Barzaghi F, Passerini L, Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: A paradigm of immunodeficiency with autoimmunity. Front Immunol 2012; 3: 211.
14. Katoh H, Zheng P, Liu Y. FOXP3: Genetic and epigenetic implications for autoimmunity. J Autoimmun 2013; 41: 72–78.
15. Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3 + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10: 744–755.
16. Elinav E, Waks T, Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology 2008; 134: 2014–24.
17. Tsang JY, Tanriver Y, Jiang S, et al. Conferring indirect allospecificity on CD4 + CD25 + Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2008; 118: 3619–3628.
18. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4 + CD25 + regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109: 827–835.
19. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011: 3: 83ra42.
20. Krustrup D, Madsen CB, Iversen M, Engelholm L, Ryder LP, Andersen CB. The number of regulatory T cells in transbronchial lung allograft biopsies is related to FoxP3 mRNA levels in bronchoalveolar lavage fluid and to the degree of acute cellular rejection. Transpl Immunol 2013: 29: 71–75.
21. Krystufkova E, Sekerkova A, Striz I, Brabcova I, Girmanova E, Viklicky O. Regulatory T cells in kidney transplant recipients: The effect of induction immunosuppression therapy. Nephrol Dial Transplant 2012; 27: 2576–2582.
22. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4 + T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398–407.
23. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921–3928.
24. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117: 1061–1070.
25. Trzonkowski P, Bieniaszewska M, Juscinska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4 + CD25 + CD127- T regulatory cells. Clin Immunol 2009; 133: 22–26.
26. Theil A, Tuve S, Oelschlagel U, et al. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy 2015; 17: 473–486.
27. Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015: 7: 315ra189.
28. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets – results of one year follow-up. Clin Immunol 2014; 153: 23–30.
29. Safinia N, Vaikunthanathan T, Fraser H, et al. Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation. Oncotarget 2016: 7: 7563–7577.
30. Afzali B, Edozie FC, Fazekasova H, et al. Comparison of regulatory T cells in hemodialysis patients and healthy controls: Implications for cell therapy in transplantation. Clin J Am Soc Nephrol 2013; 8: 1396–1405.
31. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 2013; 13: 3010–3020.
32. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4 + CD25 + Foxp3 + regulatory T lymphocytes. Nat Med 2008; 14: 88–92.
33. Lee K, Nguyen V, Lee KM, Kang SM, Tang Q. Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. Am J Transplant 2014; 14: 27–38.
34. Landwehr-Kenzel S, Issa F, Luu SH, et al. Novel GMP-compatible protocol employing an allogeneic B cell bank for clonal expansion of allospecific natural regulatory T cells. Am J Transplant 2014; 14: 594–606.
35. Boardman D, Maher J, Lechler R, Smyth L, Lombardi G. Antigen-specificity using chimeric antigen receptors: The future of regulatory T-cell therapy? Biochem Soc Trans 2016; 44: 342–348.
36. Maher J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012; 2012: 278093.
37. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725–733.
38. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011: 3: 95ra73.
39. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified t cells for acute lymphoid leukemia. N Engl J Med 2013: 368: 1509–1518.
40. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013: 5: 177ra38.
41. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results. Blood 2012; 119: 3940–3950.
42. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099–4102.
43. Kohn DB, Dotti G, Brentjens R, et al. CARs on track in the clinic. Mol Ther 2011; 19: 432–438.
44. Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 2009; 136: 1721–1731.
45. Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther 2014; 22: 1018–1028.
46. Fransson M, Piras E, Burman J, et al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation 2012; 9: 112.
47. Lee JC, Hayman E, Pegram HJ, et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res 2011; 71: 2871–81.
48. Jethwa H, Adami AA, Maher J. Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: Is now the right time? Clin Immunol 2014; 150: 51–63.
49. MacDonald KG, Hoeppli RE, Huang Q, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest 2016: 126: 1413–1424.
50. Watkins NA, Brown C, Hurd C, Navarrete C, Ouwehand WH. The isolation and characterisation of human monoclonal HLA-A2 antibodies from an immune V gene phage display library. Tissue Antigens 2000; 55: 219–228.
51. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: An open-source platform for biological-image analysis. Nat Methods 2012; 9: 676–682.
52. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998; 188: 619–626.
53. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998; 161: 2791–2797.
54. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002; 20: 70–75.
55. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822–1826.
56. Hombach AA, Kofler D, Hombach A, Rappl G, Abken H. Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2. J Immunol 2007; 179: 7924–7931.
57. Carlsson B, Forsberg O, Bengtsson M, Totterman TH, Essand M. Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy. Prostate 2007; 67: 389–395.
58. Scotta C, Esposito M, Fazekasova H, et al. Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica 2013; 98: 1291–1299.
59. Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27: 635–646.
60. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21: 589–601.
61. Ma L, Cheung KC, Kishore M, Nourshargh S, Mauro C, Marelli-Berg FM. CD31 exhibits multiple roles in regulating T lymphocyte trafficking in vivo. J Immunol 2012; 189: 4104–4111.
62. Green H, Easley K, Iuchi S. Marker succession during the development of keratinocytes from cultured human embryonic stem cells. Proc Natl Acad Sci USA 2003; 100: 15625–15630.
63. Burt C, Cryer C, Fuggle S, Little AM, Dyer P. HLA-A, -B, -DR allele group frequencies in 7007 kidney transplant list patients in 27 UK centres. Int J Immunogenet 2013; 40: 209–215.